ADC · 난소암

12개 · ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved12 programs
ADCCurated CoreFDAstaleRochevedotin, rituximab, cycloph…Phase 3

Polatuzumab Vedotin (Polatuzumab Vedotin)

Large B-Cell Lymphoma · FRα

#FR#ADC#Phase3#FDA-approved#BioJungboMoa-pick+5
Trials 91Status Recruiting
ADCCurated CoreFDAAbbVieDM4 (maytansinoid, tubulin …Approved

mirvetuximab soravtansine (Elahere, IMGN853, mirvetuximab-soravtansine-gynx)

FRα-positive platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer · FRα (folate receptor alpha)

#FRfolatereceptoralpha#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 32Status Approved
ADCStandard DatabasestaleFavrillederuxtecan for metastatic b…Phase 2

Antibody-Drug Conjugate Therapy (Antibody-Drug Conjugate Therapy)

Metastatic Bladder Urothelial Carcinoma; Metastatic Renal Pelvis and Ureter Urothelial Carcinoma · FRα

#FR#ADC#Phase2#Popular#antibody-drug-conjugate+5
Trials 58Status Recruiting
ADCStandard DatabasestaleSeagenPhase 2

brentuximab vedotin (Adcetris, Brentuximab Vedotin - induction)

Refractory Peripheral T-Cell Lymphoma; Relapsed Peripheral T-Cell Lymphoma · FRα

#FR#ADC#Phase2#antibody-drug-conjugate#RefractoryPeripheralT-CellLympho+2
Trials 24Status Active
ADCStandard DatabasestaleAbbViePhase 3

Mirvetuximab soravtansine plus Bevacizumab (Mirvetuximab soravtansine plus Bevacizumab)

Ovarian Cancer; Peritoneal Cancer · Ovarian Cancer

#OvarianCancer#ADC#Phase3#antibody-drug-conjugate#PeritonealCancer+1
Trials 6Status Recruiting
ADCLimited DatastaleSeagen Inc.Phase 2

cBR96-Doxorubicin Immunoconjugate (SGN-15, SGN-15 (cBR96-Doxorubicin Immunoconjugate))

Prostatic Neoplasms · Ovarian Neoplasms

#OvarianNeoplasms#ADC#Phase2#antibody-drug-conjugate#ProstaticNeoplasms+1
Trials 5Status Active
ADCLimited DatastaleSeagenPreclinical

Brentuximab-Vedotin associated with Bendamustine (Brentuximab-Vedotin associated with Bendamustine)

Relapsed or Refractory Hodgkin Lymphoma · FRα

#FR#ADC#Preclinical#antibody-drug-conjugate#RelapsedorRefractoryHodgkinLymph+1
Trials 1Status Active
ADCLimited DatastaleGenmabPhase 2

HuMax-AXL-ADC (Enapotamab vedotin, Enapotamab vedotin (HuMax-AXL-ADC))

Ovarian Cancer; Cervical Cancer · Ovarian Cancer

#OvarianCancer#ADC#Phase2#antibody-drug-conjugate#CervicalCancer+1
Trials 1Status Active
ADCLimited DatastaleSeagen, a wholly owned subsidia…Phase 1

Felmetatug Vedotin (Felmetatug Vedotin)

Ovarian Neoplasms; Peritoneal Neoplasms · HER2

#HER2#ADC#Phase1#antibody-drug-conjugate#OvarianNeoplasms+2
Trials 1Status Discontinued
ADCLimited DatastaleAbbViePhase 1

Mirvetuximab + SL-172154 (Mirvetuximab + SL-172154)

Platinum-resistant Ovarian Cancer; Fallopian Tube Cancer · Platinum-resistant Ovarian Cancer

#Platinum-resistantOvarianCancer#ADC#Phase1#antibody-drug-conjugate#FallopianTubeCancer+1
Trials 1Status Active
ADCLimited DatastaleThe First Affiliated Hospital o…Phase 2

sacituzumab govitecan (Trodelvy, Sacituzumab Tirumotecan Combined with Bevacizumab)

Platinum-resistant Recurrent Ovarian Cancer (PROC) · Platinum-resistant Recurrent Ovarian Can

#Platinum-resistantRecurrentOvari#ADC#Phase2#antibody-drug-conjugate#The
Trials 1Status Recruiting
ADCLimited DatastaleBoryung Pharmaceutical Co., LtdPhase 2

Trastzumab Deruxtecan (Trastzumab Deruxtecan)

Ovarian Cancer; Ovarian Carcinoma, Recurrent · Ovarian Cancer

#OvarianCancer#ADC#Phase2#antibody-drug-conjugate#OvarianCarcinoma+2
Trials 1Status Recruiting